D2C7-IT: Clinical Trials

4 trials of D2C7-IT, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 completed. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Recruiting 3, Completed 1
Phase 21Recruiting 1

Follow D2C7-IT: new trials by email Literature Review of D2C7-IT trials Research Report on D2C7-IT

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
D2C7-IT, 2141 V11 - Recurrent Glioblastoma IDH Wildtype
Phase 1RecruitingDarell Bigner462025-03-172026-10-21
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
D2C7-IT, 2141-V11 - Newly Diagnosed MGMT Unmethylated Glioblastoma
Phase 1 / Phase 2RecruitingDarell Bigner502023-09-062026-10-16
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
D2C7-IT, 2141-V11 - Glioma, Malignant
Phase 1RecruitingDarell Bigner902021-07-092026-06-04
D2C7 for Adult Patients With Recurrent Malignant Glioma
D2C7-IT - Malignant Glioma, Brain Tumor, Recurrent
Phase 1CompletedDarell Bigner812015-05-052026-10-23

Conditions studied

Glioblastoma (3)  ·  Glioma (2)  ·  Brain Neoplasms (1)

Sponsors

Darell Bigner (4)

Countries

United States (4)

Top investigators

Annick Desjardins, MD (1)  ·  Annick Desjardins, MD, FRCPC (1)  ·  Annick Desjardins, MD,FRCPC (1)  ·  Daniel Landi, MD (1)

Results publications

PMID 28013405, PMID 28286803, PMID 36753564, PMID 42888247